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Apparent redundancy is a recurrent theme in innate immunity in various domains including 
inflammatory cytokines, chemokines and pattern recognition receptors. While sharing core 
function, different mediators may subserve distinct functions related for instance to production and 
release (e.g. IL-1α versus IL-1β), predominantly local versus systemic function (e.g. PTX3 versus 
C-reactive protein) or fine tuning of innate and adaptive responses (chemokines). Based on hard-
wired phagocyte recruitment and regulation by a wide spectrum of chemokines and conventional  or 
atypical receptors, I argue that  trafficking of phagocytic cells is a robust output of the chemokine 
system, resistant to genetic or environmental variation. In general, I speculate that the apparent 
overlap and redundancy observed in core functions represents an evolutionary strategy to preserve 




 Cytokines and chemokines exhibit a considerable degree of overlap of function. A classic 
example is provided by IL-1 for which two isoforms (α and β) have long been known to exist [1, 2]. 
IL-1α and IL-1β interact with the same receptor complex, activate the MyD88 pathway [3] and 
elicit the same pattern of responses in different cell types [4]. Moreover, the IL-1 spectrum of 
responses has long been known to overlap with that of TNF, with the notable exception of cell 
killing and of divergent actions in the regulation of hematopoiesis. 
 Apparent redundancy is a recurrent theme among cytokines (e.g. IL-17), growth factors and 
chemokines [5-9]. The chemokine superfamily, with its complexity and promiscuous usage of 
receptors, is perhaps the most striking example of apparent redundancy.  Dissection of the 
regulation of production and action of seemingly redundant mediators reveals that in nature of fact 
each mediator has unique features which underlie its selection in evolution. Here, I argue that, while 
recognizing the unique functions of mediators with overlapping fingerprints, the existance of a 
shared retained function or set of function reflects darwinian selection of evolutionary essential core 
functions.  As I argued in the past [10], it is my tenet that redundancy represents a strategy to 
preserve  essential core functions in the face of evolutionary pressure. 
 
Specialization and division of labour 
I will dwell on two molecular families whose members share  essential structural features to 
illustrate specialization and division of labour as a recurrent theme. Another contribution in this 
issue of the Journal provides an original perspective on the general theme of robustness dwelling on 
tissue repair [11]. IL-1α and IL-1β are two cytokines with limited sequence homology but similar 
folding and three dimensional structures. They interact with the same signaling  receptor,  a 
heterodimer composed of IL-1R1 and an IL-1R accessory protein [2, 4, 12, 13]. Multimerization of 
the adaptor protein MyD88 leads to IRAK4 activation and ultimately NFkB activation. IL-1 is a 
prototypic inflammatory cytokine which activates a cascade of mediators with amplification and 
negative regulation loops. Moreover, IL-1 plays a key role in the activation and orientation of 
lymphoid cell mediated innate and adaptive immune responses [4]. Then why two IL-1s?  
 The pathways leading to release of IL-1α and IL-1β are shared and in part distinct 
(Fig. 1). IL-1β is only produced on demand and release requires processing by caspase 1. In 
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contrast, IL-1α is stored preformed in a variety of cell types, skin keratinocytes in particular, in 
amounts sufficient to cause death of the organism. Moreover, the pathway of regulated secterion of 
IL-1α  does not involve caspase 1. IL-1α therefore behaves as an “alarmin” with its uncontrolled 
release signaling tissue damage.  Thus the pathways of release are a major distinguishing feature 
between IL-1α and IL-1β, which share fundamental core functions. 
Monoclonal antibodies targeting IL-1α and IL-1β are currently undergoing clinical 
evaluation. Anti IL-1α has shown promising results in the treatment of cancer cachexia, while anti-
IL-1β has been shown to prevent atherosclerosis-related pathology and lung cancer incidence and 
mortality  in the large (10061 patients) Cantos trial [14, 15]. It will be interesting to assess whether 
and to what extent the clinical activity of blocking IL-1α and IL-1β mirrors the involvement of 
different pathways of production in different pathological conditions. 
Pentraxins are an evolutionary conserved family of molecules which includes C reactive 
protein (CRP), serum amyloid P component (SAP) and the long pentraxin PTX3 [16-18]. 
Pentraxins serve as fluid phase pattern recognition molecule which recognize microbial moieties 
and apoptotic cells and trigger  effector functions including complement activation and opsonic 
disposal of targeted cells. Moreover, they have a regulatory function on inflammatory reactions. 
CRP (or SAP in the mouse) is produced as an acute phase protein in huge amounts in the liver 
downstream of an IL-1-IL-6 cascade. In contrast, PTX3 is stored in neutrophil granules or produced 
in tissues on demand, leaking in the systemic circulation in small amounts. Therefore we have 
argued that CRP and PTX3 serve complementary functions mediating resistance primarily at a 
systemic and local tissue level, respectively. 
 
Redundancy for robust outputs 
Chemokines are a complex superfamily of cytokines characterized by shared structural 
organization [5, 7-10].  The eponymous function of chemokines is induction of directional cell 
migration, chemotaxis. The chemokine system is complex, with over 50 ligands originating from 48 
distinct genes (47), 18 receptors and four atypical chemokine receptors serving as decoy and 
scavengers, transporters or presenters [6, 19]. With two notable exceptions (e.g. CXCR4 and its 
ligand CXCL12; CX3CR1 and its ligand CX3CL1), chemokine receptors are promoscuous in that 
two or more ligands recognize the same receptor and one ligand frequently recognizes more than 
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one receptor. These general features of the system reflect a division of labour among receptors and 
the need for fine tuning of leukocyte traffic in innate and adaptive immunity [8, 9]. Interestingly, 
phagocytes express a wide, possibly the widest, repertoire of chemokine receptors and the capacity 
to attract monocytes is a common denominator of a substantial fraction of chemokines belonging to 
the CC, CXC and CX3C families. Moreover, virtually all inflammatory CC and CXC chemokines 
are trapped and scavenged by only 2 atypical receptors, ACKR1 and ACKR2. I therefore  argue that 
attraction of phagocytes is a robust output of the chemokine system, to be retained in face of genetic 
variation or environmental changes. 
Murine and human data are consistent with the hypothesis that from the point of view of 
fundamental phagocyte function robustness is  a feature of the chemokine system. Mice deficient 
for inflammatory chemokines or chemokine receptors have relatively subtle phenotypes [20], unlike 
CXCR4/CXCL12 deficiency which results in profound alterations in the brain, heart, intestine and 
hematopoietic system [21]. In the perspective of rubustness it is interesting that genetic deficiency 
in any one inflammatory chemokine receptor results in a wave of perturbation of the system. Since 
chemokine receptors also scavenge their ligands, deficiency of a given receptor (e.g. CCR2) results 
in higher levels of the ligands recognized (e.g. the monocyte chemotactic proteins MCPs1,2,3) 
some of which (e.g. MCP-2 and 3) are then available to interact with other cognate signaling 
receptors (e.g. CCR1 and CCR5). Inflammatory chemokine receptors of the CXC and CC family 
recognizes more than one ligand but by far the widest repertoire of ligands is bound by atypical 
receptors ACKR1 and ACKR2 [6, 22]. ACKR2 binds all inflammatory chemokines with the 
exception of one of the isoforms of CCL3. It acts as a decoy and scavenger which dampens 
inflammation and promotes resolution. ACKR1 has more complex functions in hematopoiesis and 
transport of chemokines [23], but it also can scavenge its ligands. Thus one lesson to be learned 
from atypical receptors, ACKR2 in particular, is that dampening chemokine-driven inflammation 
requires disposal of a wide repertoire of inflammatory ligands. 
Human data are consistent with the general view of robustness of the chemokine system, 
from the perspective of phagocyte function. Subjects homozygous for the ∆32 mice mutation of 
CCR5 are protected against HIV but have no developmental abnormality or increased susceptibility 
to disease. Although it is likely that the spread and persistence of ∆32 CCR5 reflects evolutionary 
advantage likely related to resistance to unknown pathogens, its lack of health impact is consistent 
with other members of the family taking over its function. Development of chemokine inhibitors as 
anti-inflammatory agents has been disappointing. I surmise that failure of anti-chemokine strategies 
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 Under many circumstances, apparent redundancy among members of cytokine families and 
pattern recognition receptors actually reflects specialized functional localization, as illustrated by 
the two examples discussed here. However several lines of evidence suggest that robustness of 
phagocyte recruitment is a built-in feature of the chemokine system allowing tissue remodeling, 
disposal of debris and a minimum immune resistance. The same general consideration may apply to 
core functions shared by cytokines and growth factors.  Robust outputs of cytokine networks may 
allow retention of sufficient core function in the face of genetic, epigenetic or environment-induced 
variation of individual components. 
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